Free Trial
NYSE:STE

STERIS (STE) Stock Price, News & Analysis

$226.85
-3.63 (-1.57%)
(As of 06/7/2024 ET)
Today's Range
$226.12
$230.67
50-Day Range
$198.94
$235.89
52-Week Range
$195.47
$254.00
Volume
302,994 shs
Average Volume
536,257 shs
Market Capitalization
$22.44 billion
P/E Ratio
59.38
Dividend Yield
0.92%
Price Target
$241.60

STERIS MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
6.5% Upside
$241.60 Price Target
Short Interest
Bearish
2.65% of Float Sold Short
Dividend Strength
Weak
Based on Four Factors
Sustainability
-2.00
Upright™ Environmental Score
News Sentiment
0.54mentions of STERIS in the last 14 days
Based on 11 Articles This Week
Insider Trading
Selling Shares
$1.80 M Sold Last Quarter
Proj. Earnings Growth
8.87%
From $9.24 to $10.06 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.60 out of 5 stars

Medical Sector

178th out of 904 stocks

Surgical Appliances & Supplies Industry

7th out of 18 stocks

STE stock logo

About STERIS Stock (NYSE:STE)

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services. It also provides capital equipment installation, maintenance, upgradation, repair, and troubleshooting services; preventive maintenance programs and repair services; instrument and endoscope repair and maintenance services; and custom process improvement consulting and outsourced instrument sterile processing services. The Applied Sterilization Technologies segment provides contract sterilization and testing services for medical device and pharmaceutical manufacturers through a network of approximately 50 contract sterilization and laboratory facilities. The Life Sciences segment designs, manufactures and sells consumable products, such as formulated cleaning chemistries, barrier, sterility assurance products, steam and vaporized hydrogen peroxide sterilizers, and washer disinfectors. This segment also offers equipment installation, maintenance, upgradation, repair, and troubleshooting services; and preventive maintenance programs and repair services. The Dental segment provides hand and electric-powered dental instruments, infection control products, conscious sedation, personal protective equipment, and water quality products for dental suite. The company serves its products and services to hospitals, other healthcare providers, and pharmaceutical manufacturers. The company was founded in 1985 and is based in Dublin, Ireland.

STE Stock Price History

STE Stock News Headlines

STERIS plc (NYSE:STE) VP Sells $267,312.56 in Stock
STERIS (NYSE:STE) Rating Increased to Buy at StockNews.com
StockNews.com Lowers STERIS (NYSE:STE) to Hold
Q4 2024 STERIS plc Earnings Call
Piper Sandler Reaffirms Their Hold Rating on Steris (STE)
STERIS Announces Dividend of $0.52 per share
See More Headlines
Receive STE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for STERIS and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Ex-Dividend for 3/22 Dividend
2/22/2024
Dividend Payable
3/22/2024
Last Earnings
5/08/2024
Today
6/08/2024
Ex-Dividend for 6/26 Dividend
6/12/2024
Dividend Payable
6/26/2024
Next Earnings (Estimated)
8/06/2024
Fiscal Year End
3/31/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical appliances & supplies
Sub-Industry
Health Care Equipment
CUSIP
85915210
Employees
18,179
Year Founded
1987

Price Target and Rating

Average Stock Price Target
$241.60
High Stock Price Target
$265.00
Low Stock Price Target
$215.00
Potential Upside/Downside
+6.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
6 Analysts

Profitability

Net Income
$378.24 million
Pretax Margin
13.68%

Debt

Sales & Book Value

Annual Sales
$5.14 billion
Cash Flow
$13.82 per share
Book Value
$63.91 per share

Miscellaneous

Free Float
97,960,000
Market Cap
$22.44 billion
Optionable
Optionable
Beta
0.85

Social Links

20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Should I Buy STERIS Stock? STE Pros and Cons Explained

Pros

Here are some ways that investors could benefit from investing in STERIS plc:

  • STERIS plc has shown consistent revenue growth over the past few quarters, indicating a strong financial performance.
  • The company has a solid dividend yield, providing investors with a steady income stream. Dividend yield is a financial ratio that shows how much a company pays out in dividends each year relative to its stock price.
  • Recent acquisitions by STERIS plc have expanded its market reach and product offerings, potentially leading to increased profitability in the future.
  • Analysts have a positive outlook on STERIS plc's stock, with many recommending it as a buy or strong buy, which could attract more investors.
  • The current stock price of STERIS plc is trading at a reasonable valuation compared to its industry peers, presenting a potential value investment opportunity for investors.

Cons

Investors should be bearish about investing in STERIS plc for these reasons:

  • STERIS plc operates in a highly regulated industry, which could lead to increased compliance costs and potential legal risks.
  • The company's high dividend payout ratio may limit its ability to reinvest in growth opportunities or withstand economic downturns. Dividend payout ratio is the proportion of earnings paid out as dividends to shareholders.
  • Market competition in the healthcare sector where STERIS plc operates is intense, which could pressure margins and hinder future growth prospects.
  • Fluctuations in foreign exchange rates could impact STERIS plc's international operations and financial performance, adding currency risk to the investment.
  • Recent global economic uncertainties and geopolitical tensions may affect STERIS plc's business operations and financial results, leading to potential volatility in its stock price.
These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Tuesday, June 4, 2024. Please send any questions or comments about these STERIS pros and cons to contact@marketbeat.com.

STE Stock Analysis - Frequently Asked Questions

Should I buy or sell STERIS stock right now?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for STERIS in the last twelve months. There are currently 3 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" STE shares.
View STE analyst ratings
or view top-rated stocks.

What is STERIS's stock price target for 2024?

6 equities research analysts have issued 12 month target prices for STERIS's stock. Their STE share price targets range from $215.00 to $265.00. On average, they expect the company's stock price to reach $241.60 in the next year. This suggests a possible upside of 6.5% from the stock's current price.
View analysts price targets for STE
or view top-rated stocks among Wall Street analysts.

How have STE shares performed in 2024?

STERIS's stock was trading at $219.85 at the beginning of 2024. Since then, STE stock has increased by 3.2% and is now trading at $226.85.
View the best growth stocks for 2024 here
.

When is STERIS's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 6th 2024.
View our STE earnings forecast
.

How were STERIS's earnings last quarter?

STERIS plc (NYSE:STE) released its quarterly earnings data on Wednesday, May, 8th. The medical equipment provider reported $2.58 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.41 by $0.17. The medical equipment provider had revenue of $1.42 billion for the quarter, compared to analysts' expectations of $1.41 billion. STERIS had a trailing twelve-month return on equity of 13.73% and a net margin of 6.95%. The business's revenue for the quarter was up 10.8% on a year-over-year basis. During the same quarter in the previous year, the business posted $2.30 EPS.
Read the conference call transcript
.

How often does STERIS pay dividends? What is the dividend yield for STERIS?

STERIS declared a quarterly dividend on Wednesday, May 1st. Stockholders of record on Wednesday, June 12th will be given a dividend of $0.52 per share on Wednesday, June 26th. This represents a $2.08 dividend on an annualized basis and a dividend yield of 0.92%. The ex-dividend date of this dividend is Wednesday, June 12th.
Read our dividend analysis for STE
.

Is STERIS a good dividend stock?

STERIS (NYSE:STE) pays an annual dividend of $2.08 per share and currently has a dividend yield of 0.90%. The dividend payout ratio is 54.45%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, STE will have a dividend payout ratio of 20.68% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for STE.

What guidance has STERIS issued on next quarter's earnings?

STERIS issued an update on its FY25 earnings guidance on Wednesday, May, 8th. The company provided EPS guidance of $9.05 to $9.25 for the period, compared to the consensus earnings per share estimate of $9.33. The company issued revenue guidance of +6.5-7.5% yr/yr or $5.473 billion to $5.524 billion, compared to the consensus revenue estimate of $5.67 billion.

What is Walter M. Rosebrough, Jr.'s approval rating as STERIS's CEO?

196 employees have rated STERIS Chief Executive Officer Walter M. Rosebrough, Jr. on Glassdoor.com. Walter M. Rosebrough, Jr. has an approval rating of 79% among the company's employees.

What other stocks do shareholders of STERIS own?

Based on aggregate information from My MarketBeat watchlists, some companies that other STERIS investors own include Johnson & Johnson (JNJ), Home Depot (HD), AT&T (T), Visa (V), AbbVie (ABBV), Abbott Laboratories (ABT), Pfizer (PFE), Gilead Sciences (GILD), Mastercard (MA) and Medtronic (MDT).

Who are STERIS's major shareholders?

STERIS's stock is owned by a number of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (11.98%), WCM Investment Management LLC (4.79%), Janus Henderson Group PLC (2.03%), Price T Rowe Associates Inc. MD (1.76%), Sustainable Growth Advisers LP (1.50%) and Champlain Investment Partners LLC (1.05%). Insiders that own company stock include Cary L Majors, Cynthia L Feldmann, Jacqueline B Kosecoff, John Adam Zangerle, Karen L Burton, Michael J Tokich, Mohsen Sohi and Renato Tamaro.
View institutional ownership trends
.

How do I buy shares of STERIS?

Shares of STE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NYSE:STE) was last updated on 6/8/2024 by MarketBeat.com Staff

From Our Partners